2018
DOI: 10.2217/pmt-2018-0018
|View full text |Cite
|
Sign up to set email alerts
|

Managing Chronic Pain: Are Gabapentinoids Being Misused?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 16 publications
0
3
0
Order By: Relevance
“…Interestingly, the ICD-10 diagnosis of substance dependence of our study subjects was set approximately three years before their first gabapentinoid prescriptions. Thus, our study findings, from a clinical sample of former adolescent psychiatric inpatients, highlights the potential for misuse of gabapentinoids and, above all, emphasizes the importance of carefully considering prescribing gabapentinoids to individuals at high-risk of drug abuse (Chiappini & Schifano, 2016;Bonnet & Scherbaum, 2017), including patients with chronic pain (Anantharamu & Govind, 2018).…”
Section: Discussionmentioning
confidence: 64%
“…Interestingly, the ICD-10 diagnosis of substance dependence of our study subjects was set approximately three years before their first gabapentinoid prescriptions. Thus, our study findings, from a clinical sample of former adolescent psychiatric inpatients, highlights the potential for misuse of gabapentinoids and, above all, emphasizes the importance of carefully considering prescribing gabapentinoids to individuals at high-risk of drug abuse (Chiappini & Schifano, 2016;Bonnet & Scherbaum, 2017), including patients with chronic pain (Anantharamu & Govind, 2018).…”
Section: Discussionmentioning
confidence: 64%
“…Baftiu et al report that antiepileptic drugs such as gabapentinoids are now being used for indications other than epilepsy [ 11 ]. Furthermore, an estimate by Anantharamu et al suggests that over 95% of gabapentinoid prescriptions are used outside the three approved indications [ 10 ]. In the USA, prescriptions for these molecules have more than tripled in the last 10 years, as described by Johansen et al and Montastruc et al [ 12 , 13 ].…”
Section: Discussionmentioning
confidence: 99%
“…As for PGB, it was approved for neuropathic pain (including post-herpetic neuralgia), fibromyalgia and convulsions [ 9 ]. However, gabapentinoids prescriptions have significantly increased in recent years in the management of non-FDA-approved musculoskeletal conditions [ 10 , 11 ].…”
mentioning
confidence: 99%